{"id":60074,"date":"2024-02-28T06:32:14","date_gmt":"2024-02-28T06:32:14","guid":{"rendered":"https:\/\/medsname.com\/mozep\/"},"modified":"2026-04-30T10:23:51","modified_gmt":"2026-04-30T10:23:51","slug":"mozep","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/mozep\/","title":{"rendered":"Mozep"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Hurtigt svar<\/h3>\n

Mozep (Pimozide 2 mg) is a butyrophenone first-generation antipsychotic. Modern use is restricted to refractory Tourette syndrome (with motor and vocal tics) and treatment-resistant delusional disorder. Strong dose-dependent QT prolongation and torsades risk \u2014 pre-treatment ECG mandatory.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Mozep at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20-hverdages leveringsvindue eller vi gensender uden ekstra omkostninger \u2014 og kvalificerer sig til vores kundeloyalitetsprogram<\/a>. Verdensomsp\u00e6ndende forsendelse er tilg\u00e6ngelig til de fleste destinationer.<\/p>\n

What Mozep is and how it works<\/h2>\n

Mozep is a pimozide tablet supplied by Sun Pharma. Available strengths: 2 mg<\/strong>. Pimozide is a butyrophenone (related to haloperidol) with selective D2 antagonism, modest 5-HT2A antagonism, and meaningful calcium-channel blockade \u2014 the latter is the basis for the QT-prolonging effect that limits its use.<\/p>\n

Modern indications: refractory Tourette syndrome (FDA approval), monosymptomatic delusional disorder (e.g. delusions of parasitosis, somatic delusions), and rare schizophrenia cases unresponsive to other agents.<\/p>\n

Indikationer og dosering<\/h2>\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdosis<\/th>\nM\u00e5ldosis<\/th>\nMaksimal dosis<\/th>\n<\/tr>\n<\/thead>\n
Tourette syndrome (adult)<\/td>\n1 mg HS<\/td>\n1\u201310 mg\/day<\/td>\n0.2 mg\/kg or 10 mg<\/td>\n<\/tr>\n
Tourette syndrome (paediatric \u2265 12 y)<\/td>\n0.05 mg\/kg HS<\/td>\n0.2 mg\/kg\/day<\/td>\n0.2 mg\/kg or 10 mg<\/td>\n<\/tr>\n
Monosymptomatic delusional disorder<\/td>\n2 mg \u00e9n gang dagligt<\/td>\n2\u20134 mg\/dag<\/td>\n\u2014<\/td>\n<\/tr>\n
Schizophrenia (refractory)<\/td>\n1 mg BID<\/td>\n2\u201310 mg\/day<\/td>\n20 mg<\/td>\n<\/tr>\n
CYP2D6 poor metaboliser \/ inhibitor<\/td>\nhalvere dosis<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Vigtige sikkerhedsovervejelser<\/h2>\n
\nFDA black-box \u2014 demensrelateret psykose<\/strong><\/p>\n

Alle atypiske antipsykotika b\u00e6rer en FDA black-box advarsel om \u00f8get d\u00f8delighed (prim\u00e6rt kardiovaskul\u00e6r og infektionsrelateret) ved brug til behandling af adf\u00e6rdsforstyrrelser hos \u00e6ldre med demens. Atypiske antipsykotika er ikke godkendt til demensrelateret psykose eller agitation.<\/strong>. Brug i denne population er off-label, sidste udvej, tidsbegr\u00e6nset og kr\u00e6ver en eksplicit risici-fordel samtale.<\/p>\n<\/div>\n

\nMandatory pre-treatment ECG and absolute contraindications<\/strong><\/p>\n

Pimozide carries a strong dose-dependent QT signal. Pre-treatment ECG required; check QTc at every dose increase; stop if QTc > 500 ms or rises > 60 ms from baseline.<\/strong> Absolute contraindications: known long QT, congenital arrhythmia syndrome, recent MI, uncompensated heart failure, hypokalaemia\/hypomagnesaemia (correct before starting), concurrent QT-prolonging drugs, and concurrent strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit juice \u2014 all raise pimozide levels and the QT signal substantially).<\/p>\n<\/div>\n

\nCYP3A4 + CYP2D6 dual substrate<\/strong><\/p>\n

Pimozide is metabolised by both CYP3A4 and CYP2D6. Strong inhibitors of either enzyme raise levels and amplify QT risk. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) and strong CYP3A4 inhibitors are absolute contraindications.<\/p>\n<\/div>\n

\nEPS, TD, and acute dystonia<\/strong><\/p>\n

As a butyrophenone, pimozide produces meaningful EPS, akathisia, acute dystonia (particularly in young men), and cumulative tardive dyskinesia. Anticholinergic adjunct (procyclidine, benztropine) sometimes used acutely.<\/p>\n<\/div>\n

Almindelige bivirkninger<\/h2>\n